- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation x
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules ×
- Software & Information Technology
- Stem Cells
- Vaccines
Method for immune tolerance induction in patients receiving enzyme replacement therapy for a variety of metabolic disorders
Unmet Need Genetically based metabolic disorders affect 1 in 2500 births globally and many of these disorders result in an enzyme deficiency. In most cases, a single enzyme is not produced by the body at…
Topical MEK inhibition as a new modality for inflammatory skin diseases and cancers
Unmet Need Inflammatory skin conditions affect many people, with a wide range of severities. Common skin disorders, such as psoriasis and atopic dermatitis, affect close to 20% of the population. Skin lesions associated with bone…
Novel small molecule mast cell activator vaccine adjuvants
Value Proposition Mast cells (MCs) are innate immune cells highly prevalent in the dermal region of the skin and in the respiratory, gastrointestinal, and urinary tract mucosa. The strategic location at the host–environment interface and…
Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases
Value Proposition Glioblastomas (GBMs) are among the most common and deadly malignant brain tumors with a mean survival time of approximately 14-15 months following diagnosis. Current treatments for GBMs include surgery, radiation, and chemotherapy, however,…